Though pharmacokinetic studies suggest accelerated biologic drug clearance with increasing body weight, evidence of obesity's impact on clinical outcomes in biologic‐treated patients with ulcerative colitis (UC) is inconsistent.
Dr Kurnool and colleagues from California, USA evaluated the impact of obesity on real world response to biological therapy in patients with UC.
In a single‐center retrospective cohort study between 2011‐2016 of biologic‐treated patients with UC, the team evaluated treatment response by baseline body mass index (BMI).
|Each 1 kg/m2 increase in BMI was associated with 4% increase in the risk of treatment failure|
|Alimentary Pharmacology & Therapeutics|
Primary outcome was treatment failure, and secondary outcomes were risk of IBD‐related surgery/hospitalization and endoscopic remission.
The researchers evaluated the independent impact of BMI on clinical outcomes.
Stratified analysis by weight‐based regimens or fixed‐dose regimens was performed.
The researchers included 160 biologic‐treated UC patients.
The team noted that each 1 kg/m2 increase in BMI was associated with 4% increase in the risk of treatment failure, and 8% increase in the risk of surgery/hospitalization.
The effect on treatment failure was seen in patients on weight‐based dosing regimens or fixed‐dose therapies.
Dr Kurnool's team concludes, "BMI is independently associated with increased risk of treatment failure in biologic‐treated patients with UC, independent of dosing regimen."